Please login to the form below

Not currently logged in
Email:
Password:

Q&A

This page shows the latest Q&A news and features for those working in and with pharma, biotech and healthcare.

Q&A: Kate Callan

Q&A: Kate Callan

We can still get kerbside pickup with COVID-19 restrictions and it always feels like a nice little indulgence. ... What’s your golden rule/piece of advice for someone starting a career in healthcare comms?

Latest news

  • Q&A: Kay Wesley Q&A: Kay Wesley

    What gets you out of bed in the morning? A cup of tea. ... It’s a knee-jerk reaction but an unhelpful one, and nearly always not true.

  • Q&A: Elizabeth Egan Q&A: Elizabeth Egan

    The thought of a great coffee, a run and the excitement about the day ahead. ... I don’t see a downside; I only see opportunities to drive change.

  • Q&A: Kate Paxton Q&A: Kate Paxton

    What’s your golden rule/piece of advice for someone starting a career in healthcare comms? ... And dig extra deep into categories that have a personal connection to you.

  • Q&A: Mike Dixon Q&A: Mike Dixon

    Which book/film would you recommend above all others and why? It’s a Wonderful Life. ... Which buzzwords/office jargon get on your nerves? ‘Let’s have a TC’.

  • Q&A: Stefi Rucci Q&A: Stefi Rucci

    You can sit at the bar for an aperitif or a glass of prosecco, or sit down for dinner. ... What’s your golden rule/piece of advice for someone starting a career in healthcare comms?

More from news
Approximately 47 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Case study: 4 Sites – Navigating the course ahead Case study: 4 Sites – Navigating the course ahead

    the critical mass needed to help shift practice at a national level, rather than just in pockets. ... board. Delegates want more from a stand- alone, including follow-up education via self-led remote learning, both on- demand and with live Q&A from KOLs.

  • Rare disease trials Q&A Rare disease trials Q&A

    With 350 million people affected worldwide, rare diseases represent a major unmet medical need. ... The selection of appropriate endpoints is crucial to provide substantial evidence of the efficacy of a drug.

  • Gene therapy market access Q&A Gene therapy market access Q&A

    Could Europe steal a march on the US if it gets cell and gene market access right? ... And frankly, as a UK taxpayer, I’m glad that that’s the case.

  • The Orkambi row explained The Orkambi row explained

    Q&A and timeline. The Orkambi row still isn’t resolved. Who is to blame for this mess? ... accept such a public offer without exposing its price negotiations elsewhere in the world.

  • Immunotherapy combination trials Q&A Immunotherapy combination trials Q&A

    What factors should sponsors weigh up when planning a new IO trial in 2019 and beyond? ... as the enthusiasm and available resources to dedicate to a study, should be selected.

More from intelligence
Approximately 17 fully matching, plus 0 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 21 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics